

10 November 2021

ASX and MEDIA RELEASE

Company Presentation - Market Eye's 6th Annual TechOpps Virtual Conference

Dotz Nano Limited (ASX:DTZ) (“**Dotz**” or the “**Company**”) an advanced technology company developing, manufacturing and commercialising marking, tracing and verification solutions, today provides the attached presentations to be made by Chair Bernie Brookes at Market Eye's 6th Annual TechOpps Virtual Conference. Mr Brookes will be presenting at 5pm AEDT on Wednesday, 10 November 2021.

The virtual conference will run over 10-11 November and feature presentations from some of Australasia's leading and emerging tech companies.

The keynote speaker for the event is federal treasurer and deputy leader of the Liberal Party, The Hon. Josh Frydenberg MP.

Attendance is free. Register for the event and view the full program at <https://techopps.live/>

-ENDS-

This announcement has been authorized for release by the Company Secretary of Dotz Nano Limited.

For further information, please contact:

Investors:

Eric Kuret

Market Eye

E: eric.kuret@marketeye.com.au

P: +61 3 9591 8904

Media:

Tristan Everett

Market Eye

E: tristan.everett@marketeye.com.au

P: +61 403 789 096

About Dotz Nano Limited

Dotz Nano Limited (ASX: DTZ) is a technology leader in research, production and marketing of anti-counterfeiting, authentication and tracing solutions.

Its unique products ValiDotz, BioDotz, Fluorensic and InSpec are exceptional solutions for numerous applications, such as: bio-imaging, liquids tagging, lubricants and DEF authentication, polymers tagging, anti-counterfeiting, brand & reputation protection and oil & gas industry.

To learn more about Dotz, please visit the website and corporate video via the following link www.dotz.tech

personal use only



Tech Ops Presentation
November 21

Disclaimer

- This presentation has been prepared by Dotz Nano Limited (**Dotz**). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in Dotz. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.
- This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Dotz. This presentation is not an offer to any person nor is it a prospectus.
- Dotz has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by Dotz or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.
- This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.
- This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of Dotz. Dotz reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).
- Neither Dotz, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001 and/or the Corporations Act 2001, and any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
- This presentation may contain forward looking statements. Forward looking statements include, but are not limited to, statements concerning Dotz's business, future prospects and other statements that are not historical facts. Such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Dotz has no intention to update or revise forward-looking statements, regardless of whether new information, future events or any other factors affect the information contained in this presentation, except where required by law
- Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in Dotz.

About Us.

(ASX: DTZ)

Public company;
traded on ASX

HQ

Australia

R&D

Israel & USA
(Third party)

**Manufacturing
Facilities**

Germany & USA
(Third Party)

Works in end-to-end Advanced Materials
Dots (CQDs) based , hardware & software
solutions, for:

- virus detection (SARS-CoV-2 and more)
- Anti-counterfeiting, brand protection & supply chain integrity

Technology.

What are Quantum dots?



Non-toxic

Made from carbon sources, Graphene Quantum Dots (GQDs) are a non-toxic advanced material



Fluoresce

GQDs absorb photons of light, then re-emit photons at a different wavelength. When exposed to UV light, GQDs fluoresce



Adjustable

The fluorescence colour can be tuned by changing the size or doping of the particle, creating unique digital fingerprints



Applications

GQDs have multiple applications, including biomedical, in-product authentication, tracing, lighting and sensors

FY21 Achievements

Commercialising tech



Secured commercial agreements for PPE authentication in multiple countries



Commercialising virus detection technology, known as the Dotz Test Kits



Provided Dotz Markers and detectors verifiable surface sanitisation solution, Active V-SRD, with Zohar Dalia



Raised ~A\$7.1m to accelerate growth

The challenge.

Brand protection and product authentication



Alcohol



Industrial
fluids



Premium
consumer
products



Industrial
products



Safety



Pharma



Tobacco

Markets & Opportunities.

Huge addressable markets:

- **\$4.2 Tr**: global counterfeit goods by 2022¹
- **\$200 B**: global anti-counterfeit packaging market by 2025²
- **\$5-13 B**: global market for anti-counterfeiting³
- **\$105.6 B**: COVID-19 Diagnostics Market⁴
- **\$13.8 B**: Global rapid medical diagnostic⁵
- **\$2.4B**: Global rapid Influenza diagnostic⁶

(1) Mordor Intelligence, Global Anti-counterfeit Packaging Market (2020-2025)
ICC (International Chamber Of Commerce), 2017

(2) MarketsandMarkets, Anti-counterfeit Packaging Market Global Forecast To 2025
KBV Research, Global Anti-Counterfeit Packaging Market Analysis (2018 - 2024)

(3) Smithers 2018 - The Future of Anti-Counterfeiting, Brand Protection and Security Packaging to 2024
Mordor Intelligence, Global Anti-counterfeit Packaging Market (2020-2025)




(4) Grand View Research - COVID-19 Diagnostics Market Size, Share & Trends Analysis Report (2021-2027)

(5) Grand View Research - Rapid Medical Diagnostic Kits Market Size, Share & Trends Analysis Report (2021-2028)

(6) TechNavio

Targeting anti-counterfeiting, tracing & bio-imaging markets

- **Multiple layers of security:**
 - **Covert, semi-forensic, forensic**
- **Fluorescent marking creating unique digital fingerprint**
- **No royalties**
 - **Patent applications**
- **End-to-end solution suitable for use by:**
 - **Large manufacturers using forensic capability for brand protection and product liability;**
 - **Distribution centers using semi-forensic functionality for supply chain verification; and**
 - **End consumers to verify product authenticity utilising a \$1 LED light**



Current “Golden-Standard” vs. Dotz™ Diagnostics

Saliva / Swab

RT-LAMP



Heating
for 17min Using two
heating blocks



Isothermal
Incubation



Positive / Negative

Results



PCR

Collection



Incubation




RNA Purification



Amplification



Detection



Results analysis



Dotz's Diagnostic Solution.

- **US\$2.1m purchase order from UAE-based Hygiene Links for the six-month supply of Dotz Test Kits for use in the UAE, Egypt and Sudan**
 - Distribution agreement grants Hygiene Links the exclusive right to sell the Dotz Test Kits in the UAE, Egypt and Sudan for a two-year period, provided minimum orders are met
- **Obtained CE Mark for nasopharyngeal and saliva-based Dotz Test Kits**
 - Clears the product for sale in the European Union (some countries will have additional regulatory requirements)
- **Successful blind clinical trial on 73 subjects in the USA#**
 - 96.7% accurate in positively detecting SARS-CoV-2
 - 100% specificity – ability to identify SARS-CoV-2 without being triggered by other viruses
 - Test results within 15-17 minutes (when using two heating blocks)
 - Visual detection by colour change of the reagents
 - Limit of Detection (LoD) of 2,500 copies per mL
- **US FDA Emergency Use Authorisation approval has been submitted and is subject to approval.**

refer ASX releases on FDA application



Key priorities for FY22.

- Targeting recurring sales within anti-counterfeiting, diagnostics and commercial cleaning sectors
- New commercial agreements with anti-counterfeiting domain
 - Advanced negotiations currently underway with multiple potential customers
- Commercialise Dotz Test Kits
 - Seek Additional regulatory approvals, including FDA Emergency Use Authorisation
 - Secure new commercial agreements
 - New distribution partners
- Commercialise Active V-SRD
 - Seek Regulatory approval to sell the product with a Dotz marker
 - Secure first commercial agreement



Dotz.

Thank you.

